Merck & Company, Inc. (NYSE:MRK)‘s stock had its “hold” rating reaffirmed by investment analysts at Berenberg Bank in a report issued on Wednesday, November 1st.
Several other equities research analysts also recently weighed in on the company. Jefferies Group LLC downgraded Merck & from a “hold” rating to an “underperform” rating in a research report on Wednesday, November 1st. BMO Capital Markets set a $68.00 target price on Merck & and gave the stock a “buy” rating in a research report on Monday, October 30th. Leerink Swann decreased their target price on Merck & from $70.00 to $69.00 and set a “market perform” rating for the company in a research report on Monday, October 30th. Citigroup Inc. raised Merck & to a “buy” rating in a research report on Monday, October 30th. Finally, J P Morgan Chase & Co set a $70.00 target price on Merck & and gave the stock a “buy” rating in a research report on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. Merck & presently has an average rating of “Hold” and an average price target of $66.87.
Merck & (NYSE:MRK) traded down $1.10 during mid-day trading on Wednesday, reaching $54.10. The company’s stock had a trading volume of 17,177,959 shares, compared to its average volume of 9,583,477. Merck & has a 1 year low of $53.63 and a 1 year high of $66.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The stock has a market capitalization of $147,550.00, a P/E ratio of 14.19, a PEG ratio of 2.38 and a beta of 0.78.
COPYRIGHT VIOLATION NOTICE: “Merck & Company, Inc. (MRK) Rating Reiterated by Berenberg Bank” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/berenberg-bank-reaffirms-hold-rating-for-merck-co-inc-mrk/1748752.html.
In other news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.25% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the company. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Merck & by 133.4% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock valued at $9,165,000 after purchasing an additional 82,454 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Merck & by 2.6% during the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock valued at $269,678,000 after purchasing an additional 107,201 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in Merck & by 41.9% in the 2nd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after buying an additional 87,443 shares in the last quarter. Stevens Capital Management LP bought a new position in Merck & in the 1st quarter worth approximately $15,126,000. Finally, Trust Co grew its holdings in Merck & by 2.8% in the 1st quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after buying an additional 1,852 shares in the last quarter. 72.98% of the stock is owned by institutional investors.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with our FREE daily email newsletter.